Liquid Biopsy Market Summary

The global liquid biopsy market size was estimated at USD 11.85 billion in 2024 and is projected to reach USD 22.88 billion by 2030, growing at a CAGR of 11.5% from 2025 to 2030. The market is witnessing growth due to factors such as the growing prevalence of cancer, technological advancements in cancer diagnostics, and rising preference for minimally invasive cancer diagnostics. Liquid biopsy offers a safer, quicker, and more patient-friendly alternative to traditional tissue biopsy by enabling real-time monitoring of tumor progression using blood and other body fluids.

Moreover, ongoing research for the development of liquid biopsy assays and tests, aided by the rising adoption and development of multi-cancer early detection tests, is providing a major opportunity for the growth of the overall market. The capability of liquid biopsy to identify genetic mutations, treatment-resistant cancer cells, and minimal residual disease supports personalized treatment planning and enhances clinical outcomes. Increasing collaborations among diagnostic companies, hospitals, and research institutions are accelerating innovations in sequencing technologies, circulating biomarkers, digital PCR, and AI-based early screening tools.

Key Market Trends & Insights

  • North America dominated the liquid biopsy market with the largest revenue share of 51.15% in 2024, driven by strong healthcare infrastructure and early adoption of precision oncology.
  • The liquid biopsy market in the U.S. accounted for the largest market revenue share in North America in 2024 due to widespread access to advanced cancer testing and growing awareness about early diagnosis.
  • Based on technology, the multi-gene-parallel analysis (NGS) segment led the market with the largest revenue share of 76.17% in 2024, as next-generation sequencing offers high accuracy in detecting a wide range of biomarkers simultaneously.
  • Based on biomarker, the circulating tumor cells (CTC) biomarker segment led the market with the largest revenue share of 35.67% in 2024 due to its strong clinical relevance in cancer diagnosis and treatment monitoring.
  • Based on application, the cancer segment led the market with the largest revenue share of 86.31% in 2024, supported by increasing demand for early-stage detection, therapy selection, and recurrence surveillance.

Order a free sample PDF of the Liquid Biopsy Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

  • 2024 Market Size: USD 11.85 Billion
  • 2030 Projected Market Size: USD 22.88 Billion
  • CAGR (2025-2030): 11.5%
  • North America: Largest market in 2024

Key Companies & Market Share Insights

The liquid biopsy industry is driven by a mix of established leaders and emerging innovators, each employing distinct strategies to enhance their market footprint. Major players such as ANGLE plc, Oncimmune Holdings PLC, Guardant Health, Myriad Genetics, Inc., Biocept, Inc., Lucence Health Inc., Freenome Holdings, Inc., F. Hoffmann-La Roche Ltd., QIAGEN, Illumina, Inc., Thermo Fisher Scientific, Inc., Epigenomics AGmaintain dominance through continuous test innovations, acquisitions, and strategic partnerships aimed at expanding service offerings and reinforcing their global presence. For instance, in November 2023, Illumina Inc. announced the new TruSight Oncology 500 ctDNA v2, a new generation of its liquid biopsy assay for genomic profiling.

Key Players

  • ANGLE plc
  • Oncimmune Holdings PLC
  • Guardant Health
  • Myriad Genetics, Inc.
  • Biocept, Inc.
  • Lucence Health Inc.
  • Freenome Holdings, Inc.
  • Hoffmann-La Roche Ltd.
  • QIAGEN
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Epigenomics AG

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The liquid biopsy market is expected to continue expanding rapidly as cancer cases rise globally and healthcare systems shift toward precision medicine approaches. The ability of liquid biopsy to provide non-invasive, real-time tumor insights drives its adoption across diagnostics and treatment monitoring pathways. Increasing investment in genomic research, regulatory approvals for novel assays, and the emergence of multi-cancer early detection technologies will further enhance market penetration. With continuous improvements in sensitivity and biomarker analysis, liquid biopsy is positioned to transform cancer care, offering earlier intervention and improved survival rates, which will sustain strong market growth through 2030.